Trevi Therapeutics GAAP EPS of -$0.12 misses by $0.01
- Trevi Therapeutics press release (NASDAQ:TRVI): Q3 GAAP EPS of -$0.12 misses by $0.01.
- Cash and cash equivalents of $66.57M
Net loss: For the third quarter of 2022, the Company reported a net loss of $8.3 million, compared to a net loss of $7.3 million in the same period in 2021. The increase was primarily due to the increase in R&D expenses.